We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$109B
AUM Growth
+$10.4B
Cap. Flow
-$1.13B
Cap. Flow %
-1.03%
Top 10 Hldgs %
18.72%
Holding
8,634
New
1,446
Increased
2,646
Reduced
3,048
Closed
1,267

Sector Composition

Rank Sector Weight
1 Technology 7.41%
2 Consumer Discretionary 6.04%
3 Financials 5.89%
4 Industrials 4.61%
5 Healthcare 4.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RCKT icon
6801
CALL
Rocket Pharmaceuticals
RCKT
$381M
$69K ﹤0.01%
8,650
+4,050
+88% +$27.2K
KONA
6802
CALL
DELISTED
Kona Grill, Inc.
KONA
$69K ﹤0.01%
+11,000
New +$88.7K
STB
6803
DELISTED
Student Transportation Inc
STB
$69K ﹤0.01%
11,736
-1,464
-11% -$8.19K
PDS
6804
PUT
Precision Drilling
PDS
$1.09B
$68K ﹤0.01%
720
+130
+22% +$13.6K
QUIK icon
6805
PUT
QuickLogic
QUIK
$234M
$67K ﹤0.01%
2,700
-264
-9% -$6.04K
SEEL
6806
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
0
PETX
6807
CALL
DELISTED
Aratana Therapeutics, Inc.
PETX
$67K ﹤0.01%
+12,600
New +$85.1K
MNKD icon
6808
CALL
MannKind Corp
MNKD
$1.24B
$66K ﹤0.01%
44,300
-18,180
-29% -$47.7K
TRQ
6809
CALL
DELISTED
Turquoise Hill Resources Ltd
TRQ
$66K ﹤0.01%
+2,160
New +$72.8K
PDLI
6810
CALL
DELISTED
PDL BioPharma, Inc.
PDLI
$66K ﹤0.01%
29,100
-13,100
-31% -$29K
PDLI
6811
PUT
DELISTED
PDL BioPharma, Inc.
PDLI
$66K ﹤0.01%
29,100
+14,300
+97% +$31.6K
CARM
6812
DELISTED
Carisma Therapeutics
CARM
$65K ﹤0.01%
+1,480
New +$61.7K
VVUS
6813
CALL
DELISTED
Vivus Inc
VVUS
$65K ﹤0.01%
5,760
-2,310
-29% -$26.2K
GERN icon
6814
CALL
Geron
GERN
$943M
$64K ﹤0.01%
+28,400
New +$60.5K
MUFG icon
6815
PUT
Mitsubishi UFJ Financial
MUFG
$260B
$64K ﹤0.01%
+10,100
New +$66.1K
MRNS
6816
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$64K ﹤0.01%
+8,956
New +$48.1K
MTL
6817
PUT
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
$64K ﹤0.01%
12,000
+1,300
+12% +$7.33K
ETRM
6818
DELISTED
EnteroMedics Inc.
ETRM
$64K ﹤0.01%
+11,119
New +$82.2K
ARAY icon
6819
CALL
Accuray
ARAY
$33.2M
$63K ﹤0.01%
+13,200
New +$68.8K
CLMT icon
6820
Calumet Specialty Products
CLMT
$4.19B
$63K ﹤0.01%
16,469
-21,557
-57% -$85.3K
FATE icon
6821
Fate Therapeutics
FATE
$300M
$63K ﹤0.01%
+13,746
New +$50.3K
RDNT icon
6822
RadNet
RDNT
$6.01B
$63K ﹤0.01%
+10,629
New +$63.2K
CSCI
6823
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$63K ﹤0.01%
+211
New +$62.1K
GAU
6824
PUT
Galiano Gold
GAU
$547M
$62K ﹤0.01%
23,700
+7,200
+44% +$22.3K
NTBL
6825
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$62K ﹤0.01%
+323
New +$62K

Similar funds

Ken Griffin's Q1 2017 Portfolio in Review

As of Q1 2017, Ken Griffin held 8,634 positions worth $109B, up 11% from $99B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Ken Griffin's Q1 2017 filing shows 1,446 new, 2,646 increased, 3,048 reduced and 1,267 closed positions. Its largest new stake was Meta Platforms (Facebook): 4,289,917 shares worth $609M. The largest sale was Alphabet (Google) Class A, an estimated $482M.

By sector, the portfolio is most concentrated in Technology at 7.4% of assets, up from 5.7% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Ken Griffin's largest Q1 2017 buy was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
  • Ken Griffin added most to Microsoft in Q1 2017, an estimated $529M increase.
  • Ken Griffin's biggest Q1 2017 reduction was Alphabet (Google) Class A, cutting an estimated $482M.
  • Ken Griffin fully exited Celgene Corp in Q1 2017, selling an estimated $341M.
  • Ken Griffin's ten largest holdings make up 19% of its $109B portfolio in Q1 2017.
  • Ken Griffin opened 1,446 new positions and closed 1,267 in Q1 2017.
  • Ken Griffin's portfolio value rose 11% quarter-over-quarter to $109B.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.